A potential coronavirus vaccine developed by Oxford University in the UK with pharmaceutical giant AstraZeneca has produced a strong immune response in a large, early-stage human trial, according to newly released data published Monday in the medical journal The Lancet.
Killer T cells offer long-term protection
The researchers said the vaccine produced both antibodies and killer T-cells to combat the infection. Neutralizing antibodies, which scientists believe is important to gain protection against the virus, were detected in participants after 28 days.
80 percent confidence of vaccine by September
A spokeswoman for Oxford University said on July 15 that the team was awaiting confirmation from a scientific journal of the publication date and time for the data, but gave no further details. The Oxford team previously said they are 80 percent confident they will have a working jab by September.
